AstraZeneca CFO Aradhana Sarin (L) and CEO Pascal Soriot at the company's investor day (Ayisha Sharma for Endpoints News)
May 21, 2024 11:16 AM EDTUpdated May 21, 09:14 PM
R&D
Pharma

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

Ayisha Sharma

News Reporter

Amber Tong

Senior Editor

CAM­BRIDGE, UK — Pas­cal So­ri­ot has set an am­bi­tious $80 bil­lion rev­enue tar­get for As­traZeneca by 2030. But he’s not stop­ping there. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times